Susan Shin, MD
Neurology · New York, NYNPI 1871790105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 33.5% of the total.
Across 223 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Argenx US, Inc.$985
- Xeris Pharmaceuticals, Inc.$454
- UCB, Inc.$452
- Merz Pharmaceuticals, LLC$434
- plus $830 from 11 others
Across 7 payments — averaging $8862.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$62K
What the payments were for
- Food & beverage$6,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 108 | $2,284 |
| AstraZeneca(2 entities) | 37 | $1,373 |
| Argenx US, Inc. | 13 | $985 |
| Xeris Pharmaceuticals, Inc. | 25 | $454 |
| UCB, Inc. | 6 | $452 |
| Merz Pharmaceuticals, LLC | 15 | $434 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Merz North America, Inc. | 4 | $148 |
| Grifols USA, LLC | 1 | $135 |
| Natus Medical Incorporated | 1 | $90 |
| Alnylam Pharmaceuticals Inc. | 2 | $85 |
| Akcea Therapeutics, Inc. | 3 | $76 |
| Strongbridge US Inc. | 3 | $44 |
| Sanofi | 1 | $35 |
| Averitas Pharma Inc. | 1 | $24 |
| GRT US Holding, Inc. | 1 | $23 |
| CSL Behring | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,812 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 26 | $1,459,431 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 19 | $483,433 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $209,435 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $189,406 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $177,080 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 29 | $143,749 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 22 | $11,199 |
| Pyridostigmine Bromide | 47 | $3,579 |
| Mycophenolate Mofetil | 20 | $2,292 |
| Gabapentin | 38 | $642 |
| Solu-CortefHydrocortisone Sodium Succ/Pf | 13 | $630 |
| Sodium Chloride0.9 % Sodium Chloride | 24 | $278 |
| Duloxetine Hcl | 12 | $254 |
| Prednisone | 36 | $246 |
| Tramadol Hcl | 11 | $232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart | $985 | $1,459,43126 claims |
| CSL BehringPrivigen | $22 | $189,40632 claims |
| Grifols USA, LLCGamunex-C | $135 | $177,08012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.